{"id":"NCT00388505","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis","officialTitle":"A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2006-10-17","resultsPosted":"2012-07-24","lastUpdate":"2012-07-24"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Tobramycin Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Tobramycin Solution for Inhalation","otherNames":[]}],"arms":[{"label":"Tobramycin inhalation powder (TIP)","type":"EXPERIMENTAL"},{"label":"Tobramycin solution for inhalation (TOBI)","type":"ACTIVE_COMPARATOR"}],"summary":"This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events","timeFrame":"25 weeks","effectByArm":[{"arm":"Tobramycin Inhalation Powder (TIP)","deltaMin":278,"sd":null},{"arm":"Tobramycin Solution for Inhalation (TOBI)","deltaMin":176,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":9},"locations":{"siteCount":72,"countries":["United States","Australia","Canada","Chile","Colombia","France","Germany","Hungary","Israel","Italy","Mexico","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/etrials/home.do"]},"adverseEventsSummary":{"seriousAny":{"events":85,"n":308},"commonTop":["Cough","Lung disorder","Sputum increased","Pyrexia","Dyspnoea"]}}